Published in Trials on September 25, 2014
Comparison of semi-automated methods to quantify infarct size and area at risk by cardiovascular magnetic resonance imaging at 1.5T and 3.0T field strengths. BMC Res Notes (2015) 0.89
Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials. Int J Cardiol (2015) 0.76
Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. Eur Heart J (2016) 0.75
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet (2003) 19.90
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med (1985) 11.68
Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med (2013) 8.13
The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med (1985) 7.29
Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med (2008) 7.08
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
Leukocyte-endothelial interactions. Blood (1985) 5.59
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation (2006) 5.47
Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging (2011) 4.78
Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol (1985) 4.61
Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation (1998) 4.54
The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest (1974) 4.42
TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41
Myocardial reperfusion: a double-edged sword? J Clin Invest (1985) 4.12
Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol (2001) 3.75
Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA (2012) 3.71
Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation (1998) 3.70
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol (2005) 3.15
Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J (2005) 3.12
Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol (2013) 2.99
The role of adenosine in the regulation of coronary blood flow. Circ Res (1980) 2.97
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93
Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. Lancet (2003) 2.45
Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation (2000) 2.43
Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J (2009) 2.27
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 2.23
Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study. Eur Heart J Cardiovasc Imaging (2012) 2.12
Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation (2002) 2.05
Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J (2006) 1.86
Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol (2010) 1.81
Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol (1991) 1.81
Patient comprehension and reaction to participating in a double-blind randomized clinical trial (ISIS-4) in acute myocardial infarction. Arch Intern Med (2000) 1.69
Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv (2002) 1.64
Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol (1998) 1.62
Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol (1994) 1.61
Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv (2009) 1.60
High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv (2008) 1.57
In vivo T2-weighted magnetic resonance imaging can accurately determine the ischemic area at risk for 2-day-old nonreperfused myocardial infarction. Invest Radiol (2008) 1.55
Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn (1996) 1.54
Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol (2010) 1.50
Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol (2008) 1.50
Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation (2000) 1.49
Early electrocardiographic findings and MR imaging-verified microvascular injury and myocardial infarct size. JACC Cardiovasc Imaging (2009) 1.47
Intramyocardial hemorrhage and microvascular obstruction after primary percutaneous coronary intervention. Int J Cardiovasc Imaging (2009) 1.47
Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation (2002) 1.47
Impact of thrombus aspiration during primary percutaneous coronary intervention in cardiogenic shock complicating ST-segment elevation myocardial infarction. Cardiovasc Revasc Med (2013) 1.43
Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation (2002) 1.38
Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation (1987) 1.35
Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. Circ Cardiovasc Imaging (2011) 1.32
Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. EuroIntervention (2013) 1.28
Prediction of left ventricular remodeling and analysis of infarct resorption in patients with reperfused myocardial infarcts by using contrast-enhanced MR imaging. Radiology (2007) 1.21
Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv (2004) 1.20
Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart (2003) 1.20
Acute myocardial infarction: serial cardiac MR imaging shows a decrease in delayed enhancement of the myocardium during the 1st week after reperfusion. Radiology (2010) 1.17
Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study. Heart (2009) 1.14
Relationship between location and size of myocardial infarction and their reciprocal influences on post-infarction left ventricular remodelling. Eur Heart J (2011) 1.14
A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol (2012) 1.13
Myocardial salvage by CMR correlates with LV remodeling and early ST-segment resolution in acute myocardial infarction. JACC Cardiovasc Imaging (2010) 1.13
Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv (2002) 1.10
Cardiac magnetic resonance imaging: infarct size is an independent predictor of mortality in patients with coronary artery disease. Magn Reson Imaging (2010) 1.09
Late gadolinium-enhanced cardiovascular magnetic resonance evaluation of infarct size and microvascular obstruction in optimally treated patients after acute myocardial infarction. J Cardiovasc Magn Reson (2007) 1.09
High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J (2010) 1.09
Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol (2009) 1.06
Granulocytes cause reperfusion ventricular dysfunction after 15-minute ischemia in the dog. Circ Res (1987) 1.02
Computer-assisted myocardial blush quantification after percutaneous coronary angioplasty for acute myocardial infarction: a substudy from the TAPAS trial. Eur Heart J (2009) 0.99
Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty. Circ Cardiovasc Interv (2009) 0.99
Microvascular involvement in cardiac pathology. J Mol Cell Cardiol (1998) 0.98
No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol (2010) 0.97
Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol (2004) 0.97
Assessment of no-reflow regions using cardiac MRI. Basic Res Cardiol (2006) 0.96
The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation (1984) 0.96
Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol (2005) 0.95
Effect of impaired myocardial reperfusion on left ventricular remodeling in patients with anterior wall acute myocardial infarction treated with primary coronary intervention. Am J Cardiol (2006) 0.95
Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. Am Heart J (2010) 0.94
Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart (2011) 0.92
Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J (2005) 0.92
Lack of nitric oxide contributes to vasospasm during ischemia/reperfusion injury. Plast Reconstr Surg (1997) 0.92
Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol (2005) 0.91
Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. Exp Ther Med (2013) 0.87
New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol (2011) 0.86
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev (2013) 0.86
Clinical pharmacology of bivalirudin. Pharmacotherapy (2002) 0.85
Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J (1996) 0.85
Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol (2003) 0.85
Optimal management of acute myocardial infarction at the dawn of the next millennium. Am Heart J (1999) 0.83
Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction. Chin Med J (Engl) (2009) 0.81
Comparison of two methods to detect publication bias in meta-analysis. JAMA (2006) 7.34
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med (2005) 4.45
Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol (2011) 4.07
Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA (2002) 3.42
How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med (2005) 2.95
Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol (2008) 2.93
Assessment of non-ST-segment elevation acute coronary syndromes with cardiac magnetic resonance imaging. J Am Coll Cardiol (2004) 2.88
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis (2010) 2.67
Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. Stroke (2006) 2.64
Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ (2008) 2.63
A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B (2006) 2.23
Bivariate random-effects meta-analysis and the estimation of between-study correlation. BMC Med Res Methodol (2007) 2.13
Percutaneous coronary intervention and 1 year survival in patients treated with fibrinolytic therapy for acute ST-elevation myocardial infarction. Eur Heart J (2005) 2.08
Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care. Value Health (2011) 2.05
MR imaging of cardiac tumors and masses: a review of methods and clinical applications. Radiology (2013) 2.01
Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol (2009) 2.01
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet (2012) 2.00
Factors affecting uptake of childhood immunisation: a Bayesian synthesis of qualitative and quantitative evidence. Lancet (2002) 1.91
Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med (2010) 1.89
Reperfusion haemorrhage as determined by cardiovascular MRI is a predictor of adverse left ventricular remodelling and markers of late arrhythmic risk. Heart (2010) 1.89
Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol (2012) 1.88
The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol (2005) 1.88
Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol (2009) 1.86
Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med (2007) 1.83
An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown. Biostatistics (2007) 1.74
Determinants and functional significance of myocardial perfusion reserve in severe aortic stenosis. JACC Cardiovasc Imaging (2012) 1.73
Meta-analysis of genetic studies using Mendelian randomization--a multivariate approach. Stat Med (2005) 1.72
Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation (2007) 1.69
Clinical and cost-effectiveness of a new nurse-led continence service: a randomised controlled trial. Br J Gen Pract (2005) 1.68
Aortic regurgitation quantification using cardiovascular magnetic resonance: association with clinical outcome. Circulation (2012) 1.58
Prediction of Recurrent Events by D-Dimer and Inflammatory Markers in Patients with Normal Cardiac Troponin I (PREDICT) Study. Am Heart J (2003) 1.54
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart (2012) 1.53
Coronary artery disease: myocardial perfusion MR imaging with sensitivity encoding versus conventional angiography. Radiology (2005) 1.48
Gender differences in sympathetic neural activation following uncomplicated acute myocardial infarction. Eur Heart J (2009) 1.48
A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res (2004) 1.47
Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol (2009) 1.45
Assessment of the impedance cardiogram recorded by an automated external defibrillator during clinical cardiac arrest. Crit Care Med (2010) 1.44
Characterization of acute myocardial infarction by magnetic resonance imaging. JACC Cardiovasc Imaging (2009) 1.42
The impedance cardiogram recorded through two electrocardiogram/defibrillator pads as a determinant of cardiac arrest during experimental studies. Crit Care Med (2008) 1.42
Rescue angioplasty for failed thrombolysis in older patients: insights from the REACT trial. Int J Cardiol (2007) 1.40
Sympathetic activation and vasoregulation in response to carbohydrate ingestion in patients with congestive heart failure. Can J Cardiol (2012) 1.39
Evidence-based sample size calculations based upon updated meta-analysis. Stat Med (2007) 1.35
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J (2004) 1.34
Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. EuroIntervention (2013) 1.28
An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am J Epidemiol (2004) 1.26
Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ (2004) 1.24
Comparison of the 80-lead body surface map to physician and to 12-lead electrocardiogram in detection of acute myocardial infarction. Am J Cardiol (2003) 1.19
A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One (2013) 1.19
Timing of cardiovascular MR imaging after acute myocardial infarction: effect on estimates of infarct characteristics and prediction of late ventricular remodeling. Radiology (2011) 1.18
Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ (2004) 1.18
How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol (2007) 1.17
Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction. J Cardiovasc Magn Reson (2014) 1.16
Appearance of microvascular obstruction on high resolution first-pass perfusion, early and late gadolinium enhancement CMR in patients with acute myocardial infarction. J Cardiovasc Magn Reson (2009) 1.16
High spatial resolution myocardial perfusion cardiac magnetic resonance for the detection of coronary artery disease. Eur Heart J (2008) 1.14
A generalized weighting regression-derived meta-analysis estimator robust to small-study effects and heterogeneity. Stat Med (2012) 1.14
The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. BMC Neurol (2009) 1.12
MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction. Circ Cardiovasc Genet (2013) 1.12
Reproducibility of first-pass cardiovascular magnetic resonance myocardial perfusion. J Magn Reson Imaging (2013) 1.11
Intertechnique agreement and interstudy reproducibility of strain and diastolic strain rate at 1.5 and 3 Tesla: a comparison of feature-tracking and tagging in patients with aortic stenosis. J Magn Reson Imaging (2014) 1.11
Prognostic microRNAs after AMI. Circ Res (2013) 1.10
Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. Heart (2013) 1.08
Caseous calcification of the mitral valve complicated by embolization, mitral regurgitation, and pericardial constriction. Eur Heart J Cardiovasc Imaging (2012) 1.08
Presentation of an embolised Amplatzer septal occluder to the main pulmonary artery 2 years after implantation. Int J Cardiol (2007) 1.08
k-Space and time sensitivity encoding-accelerated myocardial perfusion MR imaging at 3.0 T: comparison with 1.5 T. Radiology (2008) 1.07
Bayesian implementation of a genetic model-free approach to the meta-analysis of genetic association studies. Stat Med (2005) 1.07
Comments on 'trying to be precise about vagueness' by Stephen Senn, Statistics in Medicine 2007; 26:1417-1430. Stat Med (2008) 1.07
Recreational drug use: a major risk factor for gastroschisis? Am J Epidemiol (2007) 1.07
The efficacy of loop diuretics in acute renal failure: assessment using Bayesian evidence synthesis techniques. Crit Care Med (2007) 1.07
Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Med Res Methodol (2011) 1.06
Design and rationale of the MR-INFORM study: stress perfusion cardiovascular magnetic resonance imaging to guide the management of patients with stable coronary artery disease. J Cardiovasc Magn Reson (2012) 1.05
Multivariate meta-analysis of mixed outcomes: a Bayesian approach. Stat Med (2013) 1.05
Predicting costs over time using Bayesian Markov chain Monte Carlo methods: an application to early inflammatory polyarthritis. Health Econ (2007) 1.04
Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the British Society of Cardiovascular Magnetic Resonance. J Cardiovasc Magn Reson (2011) 1.03
The effect of microvascular obstruction and intramyocardial hemorrhage on contractile recovery in reperfused myocardial infarction: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2013) 1.03
When to wait for more evidence? Real options analysis in proton therapy. Oncologist (2011) 1.02
Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event. BMC Med Res Methodol (2012) 1.01
Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present. J Clin Epidemiol (2004) 1.01
Estimates of systolic and diastolic myocardial blood flow by dynamic contrast-enhanced MRI. Magn Reson Med (2010) 1.00
Voxel-wise quantification of myocardial blood flow with cardiovascular magnetic resonance: effect of variations in methodology and validation with positron emission tomography. J Cardiovasc Magn Reson (2014) 1.00
Threshold haemoglobin levels and the prognosis of stable coronary disease: two new cohorts and a systematic review and meta-analysis. PLoS Med (2011) 0.99
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J (2010) 0.99
Troponin-I concentration 72 h after myocardial infarction correlates with infarct size and presence of microvascular obstruction. Heart (2007) 0.98
The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study. Cancer Epidemiol (2012) 0.98
Minimally invasive evacuation of spontaneous intracerebral hemorrhage using sonothrombolysis. J Neurosurg (2011) 0.97
Systolic versus diastolic acquisition in myocardial perfusion MR imaging. Radiology (2012) 0.97
To examine the effectiveness of a hospital-based nurse-led secondary prevention clinic. Eur J Cardiovasc Nurs (2005) 0.97